Organogenesis Holdings Inc. (ORGO): Revenue
$564.17M
Year ended 2025-12-31
$457.45M
Trailing 12 months to 2026-06-30
+7.8%
3-year compound annual growth
+10.8%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $564.17M | +17.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $482.04M | +11.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $433.14M | -3.9% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $450.89M | -3.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $467.36M | +38.2% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $338.30M | +29.6% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $260.98M | +34.9% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $193.45M | -2.5% | 2021-03-16, From 2018-01-01 |
| 2017-12-31 | $198.51M | +43.1% | 2020-03-09, From 2017-01-01 |
| 2016-12-31 | $138.73M | n/a | 2019-03-18, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $564.17M | +17.0% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $548.51M | -13.0% |
| Insmed Inc (INSM) | 2025-12-31 | $606.42M | +66.7% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $606.88M | -14.9% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $521.31M | +54.7% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $616.29M | +87.3% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $502.08M | +126.3% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $638.50M | +65.5% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.73M | +110.5% |
Compare ORGO, HCM, INSM, OPK side by side · Screen every company in Pharmaceutical Preparations ↗